← Back to search

Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Cancer discovery · 2017 · Vol. 7 (4) · pp. 410-423

Abstract

Recent studies have characterized the extensive somatic alterations that arise during cancer. However, the somatic evolution of a tumor may be significantly affected by inherited polymorphisms carried in the germline. Here, we analyze genomic data for 5,954 tumors to reveal and systematically validate 412 genetic interactions between germline polymorphisms and major somatic events, including tumor formation in specific tissues and alteration of specific cancer genes. Among germline-somatic interactions, we found germline variants in <i>RBFOX1</i> that increased incidence of <i>SF3B1</i> somatic mutation by 8-fold via functional alterations in RNA splicing. Similarly, 19p13.3 variants were associated with a 4-fold increased likelihood of somatic mutations in <i>PTEN.</i> In support of this association, we found that <i>PTEN</i> knockdown sensitizes the <i>MTOR</i> pathway to high expression of the 19p13.3 gene <i>GNA11</i> Finally, we observed that stratifying patients by germline polymorphisms exposed distinct somatic mutation landscapes, implicating new cancer genes. This study creates a validated resource of inherited variants that govern where and how cancer develops, opening avenues for prevention research.<b>Significance:</b> This study systematically identifies germline variants that directly affect tumor evolution, either by dramatically increasing alteration frequency of specific cancer genes or by influencing the site where a tumor develops. <i>Cancer Discovery; 7(4); 410-23. ©2017 AACR.</i><i>See related commentary by Geeleher and Huang, p. 354</i><i>This article is highlighted in the In This Issue feature, p. 339</i>.

Publication Types

["Journal Article"]

Keywords

[]

MeSH Terms

["GTP-Binding Protein alpha Subunits", "Gene Expression Regulation, Neoplastic", "Genome, Human", "Genomics", "Germ-Line Mutation", "Humans", "Neoplasms", "PTEN Phosphohydrolase", "Phosphoproteins", "Polymorphism, Genetic", "RNA Splicing", "RNA Splicing Factors", "TOR Serine-Threonine Kinases"]

Funding

U54 CA209891 NCI NIH HHS (United States)
P41 GM103504 NIGMS NIH HHS (United States)
T32 GM008666 NIGMS NIH HHS (United States)
P50 GM085764 NIGMS NIH HHS (United States)
UL1 TR001442 NCATS NIH HHS (United States)
U24 CA184427 NCI NIH HHS (United States)
DP5 OD017937 NIH HHS (United States)